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Abstract: Triple-negative breast cancer (TNBC) accounts for 15–20% of all breast cancers. In spite of
initial good response to chemotherapy, the prognosis of TNBC remains poor and no effective specific
targeted therapy is readily available. Recently, we demonstrated the ability of U94, the latency gene of
human herpes virus 6 (HHV-6), to interfere with proliferation and with crucial steps of the metastatic
cascade by using MDA-MB 231 TNBC breast cancer cell line. U94 expression was also associated
with a partial mesenchymal-to-epithelial transition (MET) of cells, which displayed a less aggressive
phenotype. In this study, we show the ability of U94 to exert its anticancer activity on three different
TNBC cell lines by inhibiting DNA damage repair genes, cell cycle and eventually leading to cell
death following activation of the intrinsic apoptotic pathway. Interestingly, we found that U94 acted
synergistically with DNA-damaging drugs. Overall, we provide evidence that U94 is able to combat
tumor cells with different mechanisms, thus attesting for the great potential of this molecule as a
multi-target drug in cancer therapy.
Keywords: HHV-6 U94; HSV-1 amplicon vector; triple negative breast cancer cells; gene expression
profile; DNA repair; cell cycle; apoptosis
1. Introduction
Breast cancer is the most frequently diagnosed malignancy and the second leading cause of
tumor-related deaths in women worldwide [1–3]. Every year, nearly 1.7 million of breast cancer cases
are diagnosed globally, and approximately 15–20% belong to the triple-negative (TNBC) subtype [4–6].
This family of cancer is negative for the expression of estrogen receptor (ER), progesterone receptor (PR),
and human epidermal growth factor receptor 2 (HER2). As compared with hormone receptor-positive
breast cancers, TNBCs are characterized by an extremely aggressive clinical course, younger age at
onset, worse prognosis, great prevalence of highly proliferating grade tumors at diagnosis, enhanced
metastatic potential, and poor clinical outcomes, as attested by the higher relapse and lower survival
rates [7–9]. Almost 80–90% of these tumors are invasive ductal carcinomas, while the rest are classified
as apocrine, lobular, adenoid cystic, medullary, and metaplastic [10]. Moreover, at diagnosis, these
tumors are positive for lymph-vascular invasion and have already metastasized to lymph-nodes [11].
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Due to the lack of ER, PR and HER2 receptors, TNBCs do not respond to hormone-based therapies,
therefore chemotherapy still remains the standard of care treatment. The actual therapeutic approaches
are represented by cytotoxic chemotherapy targeting DNA (i.e., platinum compounds), cell division
(microtubule stabilizers, such as taxanes), and cell proliferation (anthracycline) [5,12]. However, an
optimal chemotherapy regimen for TNBC therapy has to be established. Several other agents are being
developed in the setting of managing TNBC including inhibitors of Poly (ADP-ribose) polymerase
(PARP), angiogenesis, epidermal growth factor receptor (EGFR), Tyrosine kinases, mammalian target
of rapamycin (mTOR), and statins [5,12,13].
Viruses represent a cancer cause and solution. Indeed, beside their role in promoting cancer
development, in the last decades the virotherapy using oncolytic viruses has been proposed as a
promising cancer therapy [14,15]. Some viruses, such as herpesviruses, express a handful of genes
during latency that are known to manipulate different cell functions, particularly those affecting the
life span and proliferative potential of the latently infected cells. In particular, HHV-6 expresses
during latency U94, a nuclear targeting protein [16] that possesses DNA-binding, exonuclease and
helicase-ATPase activities [17–20] and interacts with TATA-binding protein [19] suggesting a role for
the viral protein in viral gene regulation and DNA replication.
Previous studies demonstrated that the stable expression of U94 suppressed transformation
mediated by the oncogene H-ras in NIH 3T3 [21] and tumorigenesis of prostate cancer PC3 cell
line [22]. Recently, we demonstrated the ability of the viral protein to interfere with the individual
steps of the metastatic cascade by using MDA-MB 231 cell line [23]. Indeed, the expression of the viral
protein delivered by a herpes simplex virus type-1-based amplicon vector (HSV-1) strongly inhibited
cell migration, invasiveness and clonogenicity of breast cancer cells through the downmodulation
of the proto-oncogene Src and its downstream signaling pathways. Interestingly, the block of the
metastatic events was accompanied with a partial mesenchymal-to-epithelial transition (MET) and
with the S phase inhibition of the cell cycle. All these data were confirmed in in vivo experiments in
which we found that the viral protein exerted a long-term control of tumor growth, invasiveness and
metastatization [23]. Fascinatingly, U94 was able to create a tumor microenvironment unfavorable
to neo-vessels formation as demonstrated by the lack of blood vessels infiltrating the U94 positive
tumors, an event inhibiting the supply of growth factors to the malignant cells [23]. Indeed, it has been
demonstrated that the expression of the latency gene strongly inhibits angiogenesis and migration of
blood and lymphatic human endothelial cells (ECs) in vitro and vasculogenesis ex vivo [16]. The role
of U94 in favoring a less aggressive phenotype in cancer cells was confirmed on cervical cancer cells
(HeLa) [23], whereas the antitumor capability of U94 was further demonstrated in glioma cell lines
U251 and U87 [24,25].
The nuclear localization of the protein suggests that it might bind to DNA sequences and regulate
transcription. In order to gain deep insight on the mechanisms of action of the viral protein, we
characterized its molecular targets by performing comprehensive gene expression profile. In the
current study, we demonstrate that U94 is able to induce apoptosis following downmodulation of
DNA repair gene expression. Moreover, we identify U94 as a chemosensitizer molecule for TNBCs.
2. Results
2.1. U94 Alters the Transcriptome Profile of MDA-MB 231 Cells
To better understand the mechanisms underlying the anti-proliferative effect of U94, we conducted
a comprehensive gene expression analysis on U94-expressing (U94+) MDA-MB 231 breast cancer
cells. We first applied a hierarchical clustering algorithm to analyze similarities among samples and
among genes, using data obtained from the expression profiles of all samples. Figure 1A shows that
samples - examined in quadruplicate to validate the reproducibility and reliability of our experimental
procedure - clustered into three major groups on the basis of their expression profiles. Unsupervised
hierarchical clustering revealed that not treated (NT) and EGFP-expressing (EGFP+) cells have a similar
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transcriptome profile, whereas U94+ cells segregated apart from the other two groups (Figure 1A).
Moreover, Principal Component Analysis (PCA) [26] confirmed that U94+ cells exhibited a completely
different gene expression profile, indicating that U94 profoundly impacted on cancer cell biology
(Figure 1B). Among the 18537 genes available in our microarray platform, after normalization and
filtering procedures, we found 2381 genes differentially expressed at False Discovery Rate (FDR) < 0.05
between U94+ and EGFP+ MDA-MB 231 cells. Specifically, 1523 gene were downmodulated, and 858
genes were upmodulated in U94+ cells as compared to EGFP+ cells (Supplementary Table S1).
Figure 1. Transcriptional profile of MDA-MB 231 breast cancer cells expressing U94. (A) Unsupervised
hierarchical clustering of MDA-MB 231 breast cancer cell line not treated (NT) (green), expressing
EGFP (EGFP+) control (red) or expressing U94 (U94+) (blue) performed on 18537 genes obtained after
normalization and filtering procedures (n = 4 samples/group). (B) Principal Component Analysis (PCA)
conducted on 18537 genes obtained after normalization and filtering procedures (n = 4 samples/group)
expressed by MDA-MB 231 cells NT (green), EGFP+ control (red) or U94+ (blue). Each dot represents
a sample.
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2.2. U94 Induces Downregulation of Specific Gene sets in MDA-MB 231 Breast Cancer Cells
Functional analysis, performed by Ingenuity Pathways Analysis (IPA), of the 2381 genes with
FDR < 0.05 revealed that pathways related to cell cycle progression and DNA damage response
were downregulated in U94+ MDA-MB 231 cells as compared to EGFP+ cells (Figure 2A). Pathways
associated with cholesterol biosynthesis also appeared to be influenced by U94 expression (Figure 2A).
The ability of U94 in affecting cell cycle and DNA repair genes was also confirmed by network analysis
since “DNA Replication, Recombination and Repair, Cell Cycle, Cell Morphology” was the network
displaying the highest score (Figure 2B, left panel). To further corroborate our findings, we analyzed
our microarray data by Gene Set Enrichment Analysis (GSEA) [27–29], performed to identify over-
or under-represented pathways in U94+ compared to EGFP+. GSEA analysis showed that a total
of 241 different gene sets reached the significance threshold of FDR < 0.25. 240/241 pathways were
under-expressed in U94+ versus EGFP+ cells, indicating again that the U94 protein was able to switch-off
the cellular machinery. Of note, the first 15 significantly enriched gene sets (all downmodulated in
U94+ versus EGFP+ cells) were related to cell cycle progression and DNA replication (Figure 2C),
confirming IPA analysis.
In order to validate our microarray data, four representative genes were selected from the 1523
downmodulated gene list for their involvement in cell cycle regulation and DNA repair mechanisms.
mRNA level was evaluated by real-time PCR analysis. In particular, we examined the expression
level of the cyclin-dependent kinase inhibitor 3 (CDKN3), Non-SMC Condensin II Complex Subunit
G2 (NCAPG2), Ndc80 kinetochore complex component (NUF2) and High Mobility Group Box 1
(HMGB1) genes, which are involved either in cancer cell proliferation or in mediating DNA repair
processes. [30–39]. The real-time PCR analysis confirmed the microarray data (Figure 3). Indeed,
the mRNA levels of CDKN3, NCAPG2, NUF2, and HMGB1 genes were found to be downregulated
in U94+ cells, as compared to control (EGFP+) cells. Taken together, these data on one side further
confirm our previous evidences on the ability of U94 to inhibit tumor cell proliferation causing the
breast cancer cell cycle arrest [23] while, on the other side, they attest for the ability of U94 to interfere
with the breast cancer cell DNA repair mechanisms leading to inhibition of their survival.
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Figure 2. Functional analysis performed on differentially expressed genes in U94+ cells. (A) Top 15
canonical pathways differentially regulated between U94+ and EGFP+ MDA-MB 231 cells. These pathways
are the results of Ingenuity Pathway analysis (IPA) “Core Analysis” conducted on 2381 genes with FDR
< 0.05 differentially expressed between U94+ and EGFP+ MDA-MB 231 cells. Graph shows category
scores. The yellow line (threshold) indicates the minimum significance level (scored as −log(p-value) from
Fisher’s exact test). Stacked bar chart shows the percentage of genes downregulated (green), upregulated
(red) and genes not overlapping with our data set (white) in each canonical pathway. The number at the
top of each bar indicates the total number of genes present in the considered canonical pathway. (B) Top
10 molecular networks revealed by IPA analysis of 2381 genes with False Discovery Rate (FDR) < 0.05
differentially expressed between U94+ and EGFP+ MDA-MB 231 cells. (Right Panel) The most significant
molecular network, “DNA Replication, Recombination and Repair, Cell Cycle, Cell Morphology”. Node
color indicates up- (red) and downregulated genes (green). Node shapes represent functional classes of
gene products. (C) Barplot of the Normalized Enrichment Score (NES) for the top 15 significant pathways
identified by GSEAPreranked analysis comparing U94+ and EGFP+ MDA-MB 231 breast cancer cell line.
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Figure 3. Validation of gene expression profile results by real-time PCR analysis. mRNA level of
CDKN3, NCAPG2, NUF2 and HMGB1 was determined by real-time-PCR. Results are presented
as 2−∆Ct.
2.3. U94 Induces Breast Cancer Cell Apoptosis
Induction of DNA damage following block of repair mechanisms triggers apoptosis. The main
morphological changes of the apoptotic process are nuclear shrinkage, chromatin condensation [40]
and anomalies in structure and stability of the cell membrane components [41]. In particular, the
translocation of phosphatidylserine (PS) from the inner leaflet of the plasma membrane to the cell
surface and the increased permeability of the membrane are characteristics of apoptotic cells [42].
Morphological changes on cell membranes of U94+ cells were analyzed at 6 and 24 h post-transduction,
by staining cells with a combination of fluorescently labeled Annexin V and PI, which discriminates
viable cells (Annexin V−/PI−), early apoptotic cells (Annexin V+/PI−), late apoptotic cells (Annexin
V+/PI+) and necrotic cells (Annexin V−/PI+). Flow cytometric analysis revealed that following U94
expression, breast cancer cells undergo apoptosis. As shown in Figure 4A, the percentage of apoptotic
cells was 17.22% at 6 h and increased to 45.62% at 24 h post-transduction, whereas the percentage of
apoptotic cells at baseline was 10.44% only. In particular, the percentages of early apoptotic cells (lower
right quadrant) shifted from 3.33% in NT cells to 6.31% and 8.65%, at 6 and 24 h post-transduction
respectively, while the percentages of late apoptotic cells (upper right quadrant) increased from 7.11% in
NT cells to 10.91% and 36.97% at 6 and 24 h post-transduction, respectively. Thereafter, we determined
changes in the internucleosomal fragmentation profile of genomic DNA by terminal deoxynucleotidyl
transferase dUTP nick end labeling (TUNEL) assay which detects the DNA breaks occurring during
the latest stages of apoptosis. As shown in Figure 4B, U94+ cells were TUNEL+ (FITC+), whereas NT
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cells were found to be TUNEL−. Taken together, our data demonstrate that the expression of U94
triggers breast cancer cells to undergo apoptosis.
Figure 4. U94 expression in MDA-MB 231 cells induces apoptosis. (A) MDA-MB 231, 6 and 24 h
post-transduction, were stained with Annexin V-FITC and PI. Apoptosis was assessed by flow cytometry.
The four quadrants represent living cells (lower left), early apoptotic (lower right), late apoptosis (upper
right) or necrotic (upper left) stages. Values represent the percentages of each quadrant. (B) Terminal
deoxynucleotidyl transferase-mediated dUTP Nick End Labeling (TUNEL) staining in MDA-MB 231
cells transduced or not with amplicons for 24 and 48 h. DAPI staining was used to visualize the cell
nucleus. The histograms represent the mean ± SD of apoptotic cells from two independent experiments
performed in triplicate. Statistical analysis was performed by unpaired Student’s t-test, ** p < 0.01.
Scale bar: 100 µm.
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2.4. Activation of the Intrinsic Apoptotic Pathway by U94 Expression
The pathway involved in cell death can be resumed into few critical proteins. In particular, the Bcl-2
family of proteins controls a critical step in commitment to apoptosis by regulating permeabilization of
the mitochondrial outer membrane. This family includes proteins which either promote or inhibit
apoptosis that are divided into three groups based on their primary function: antiapoptotic proteins
such as Bcl-2, proapoptotic pore-formers such as Bax and proapoptotic BH3-only proteins such as
Bad [43]. Thus, the expression levels of these key apoptotic markers in MDA-MB 231 cells upon U94
expression was evaluated by immunoblotting. As shown in Figure 5, the expression level of Bcl-2
strongly decreased in U94+ cells both at 6 h and 12 h post-transduction as compared to control cells,
whereas a concomitant increase of Bax and Bad was observed. As a consequence, the Bcl-2/Bax ratio
decreased at both time points upon the viral protein expression. Since Bad can be phosphorylated and
this phosphorylation converts the proapoptotic Bad into an antiapoptotic protein [44], we examined its
phosphorylation status upon U94 expression. As expected, U94+ cells displayed increased levels of
Bad compared to its phosphorylated form either at 6 or 12 h post-transduction (Figure 5, Figures S1 and
S4). The Bcl-2 family controls cell death primarily by regulating the mitochondrial outer membrane
permeabilization, thus leading to the release of intermembrane space proteins, caspase activation and
apoptosis [43]. We analyzed the expression levels of the executioner caspase-3, which has no activity
until it is cleaved by an initiator caspase upon apoptotic signaling events. As expected, the expression
of the active effector caspase-3 in its cleaved form was found to be increased in U94+ cells at 12 h
post-transduction, as compared to control cells (Figure 5, Figures S1 and S4). Caspase-3 is activated
in both extrinsic (death ligand) and intrinsic (mitochondrial) apoptotic pathways and its processing
and activation can be mediated by the executioner caspase-8 or -9, respectively [45–47]. To gain deep
insight into the mechanisms by which U94 induces apoptosis, we evaluated the levels of the extrinsic
and intrinsic apoptotic markers caspase-8 and caspase-9. As shown in Figure 6 (Figures S2 and S4),
caspase-8 was found to be present in its inactive (not cleaved) form in both control and U94+ cells. On
the contrary, caspase-9 in its active cleaved form, was found to be significantly higher in U94+ cells at 12
h post-transduction as compared to control cells, attesting for the involvement of the intrinsic apoptotic
pathway in U94 activity. Activation of effector caspases such as caspase-3 leads to downstream cleavage
of various cytoplasmic or nuclear substrates including poly (ADP-ribose) polymerase (PARP), which is
involved in DNA repair mechanisms and apoptosis [48]. PARP inactivation prevents depletion of NAD
and ATP, which are required for later events in apoptosis [49]. We evaluated the proteolysis of PARP
and found that the expression level of cleaved PARP strongly increased in U94+ cells as compared to
control cells (Figure 7A, Figures S3 and S4). Altogether, our data indicate that the viral protein induces
activation of the caspase-dependent intrinsic apoptotic pathway in MDA-MB 231 cells.
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Figure 5. U94 induces apoptosis through the mitochondrial pathway. Immunoblots of Bcl-2, Bax, Bad,
pBad and cleaved caspase-3 protein levels in MDA-MB 231 cells transduced or not with amplicons
for 6 and 12 h. The histograms represent the mean ± SD of three separate experiments in which band
intensities were evaluated as optical density (OD) and expressed as fold change versus control samples.
Data were analyzed for statistical significance by One-way ANOVA followed by Tukey’s post hoc test.
** p < 0.01 and *** p < 0.001 versus control samples.
Figure 6. U94 induces intrinsic apoptosis. Immunoblots of caspase-8, cleaved caspase-8, caspase-9 and
cleaved caspase-9 protein levels in MDA-MB 231 cells transduced or not with amplicons for 6 and 12 h.
The histograms represent the mean ± SD of three separate experiments in which band intensities were
evaluated as optical density (OD) and expressed as fold change versus control samples. Data were
analyzed for statistical significance by One-way ANOVA followed by Tukey’s post hoc test. *** p < 0.001
versus control samples.
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Figure 7. Late apoptosis in U94 expressing cells. Immunoblots of poly (ADP-ribose) polymerase (PARP)
protein levels in MDA-MB 231 cells transduced or not with amplicons for 24 and 48 h. The histograms
represent the mean ± SD of three separate experiments in which band intensities were evaluated
as optical density (OD) and expressed as fold change vs. control samples. Data were analyzed for
statistical significance by One-way ANOVA followed by Tukey’s post hoc test. *** p < 0.001 versus
control samples.
2.5. Synergism of U94 and DNA-Damaging Drugs against Breast Cancer Cells
Impaired DNA repair machinery is likely to increase cancer cell killing by DNA-damaging
chemotherapeutic drugs [50,51]. Therefore, we explored the possibility that U94 might act as a
chemo-sensitizer molecule. To translate our findings from molecular to cellular level, MDA-MB
231 cells expressing or not expressing U94 were exposed to cisplatin and doxorubicin, two known
DNA-damaging drugs [52,53]. As shown in Figure 8, in agreement with our previous findings [23],
U94 is per se able to reduce breast cancer cell proliferation (EGFP+ vs. U94+ cells [Mean ± SEM]: 146,182
± 4758 vs. 103,012 ± 3484, p = 0.0005). Interestingly, U94+ cells exhibited a drastic decrease in cell
growth upon cisplatin or doxorubicin treatment as compared to control cells (cisplatin-treated EGFP+
vs. U94+ cells [Mean ± SEM]: 99,801 ± 3464 vs. 27,459 ± 5488, p < 0.0001; and doxorubicin-treated
EGFP+ vs. U94+ cells [Mean ± SEM]: 54,597 ± 5781 vs. 17,248 ± 3216, p = 0.0031). The increased
efficiency of U94+ cisplatin vs. cisplatin and of U94+ doxorubicin vs doxorubicin was 49.5% and 25.6%
respectively. This finding attests for the ability of U94 to render MDA-MB 231 cells more sensitive to
the activity of DNA-damaging drugs. At the same time, U94 did not show any synergistic effect with
taxol, a microtubule inhibitor [54] (taxol-untreated vs. taxol-treated U94+ cells [Mean ± SEM]: 103,012
± 3484 vs. 88,147 ± 11,330, p = 0.9003). Indeed, the differences in cell proliferation observed upon taxol
treatment EGFP+ vs U94+ cells ([Mean ± SEM]: 144,820 ± 3705 vs. 88,147 ± 1133, p < 0.0001) are merely
related to the ability of U94 to interfere with MDA-MB 231 cell growth. Collectively, these data suggest
that U94 makes cancer cells more susceptible to DNA damaging drugs.
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Figure 8. U94 sensitizes cancer cells to DNA-damaging drugs. MDA-MB 231 cells expressing either
EGFP (blue bars) or U94 (red bars) were exposed to 100 µM of cisplatin, 10 µM of doxorubicin or 50 µM
of docetaxel. Cell proliferation was determined using an automatic cell counter. Values are reported
as mean ± SEM of four replicates. ** p < 0.01, *** p < 0.001 and **** p < 0.0001 by Two-way ANOVA
followed by Sidak’s multiple comparison test.
2.6. U94 Induces Apoptosis in Different TNBCs
The ability of U94 to affect cell cycle and DNA repair genes was also evaluated in MDA-MB 468 and
in BT-549 TNBC cell lines, by real-time PCR. The experiments were carried-out at 24 h post-transduction
with EGFP- and U94-expressing plasmids. As shown in Figure 9A, the mRNA levels of CDKN3, NCAPG2,
and HMGB1 genes were found to be downregulated in both MDA-MB 468 and BT-549 U94+ cells, as
compared to control (EGFP+) cells and NUF2 in BT-549 cells. These data further confirm the ability of U94
to inhibit tumor cell proliferation by interfering with breast cancer cell DNA repair mechanisms. To gain
deeper insight on the ability of U94 to induce apoptosis in MDA-MB 468 and BT-549 cells, we performed
the Annexin V/PI and the TUNEL assays. Morphological changes on cell membranes were analyzed at
6 and 24 h post-transduction with the U94-expressing plasmid, by staining cells with a combination of
fluorescently labeled Annexin V and PI. Flow cytometric analysis revealed that following U94 expression,
MDA-MB 468 and BT-549 cells undergo apoptosis. As shown in Figure 9B, the percentage of apoptotic
MDA-MB 468 cells was 10.8% at 6 h and increased to 29.58% at 24 h post-transduction, whereas the
percentage of apoptotic cells at baseline was only 9.57%. The percentage of apoptotic BT-549 cells was
15.88% at 6 h and increased to 37.79% at 24 h post-transduction, whereas the percentage of apoptotic cells
at baseline was only 14.08%. MDA-MB 468 U94+ cells were found to be in the early apoptotic stage at
6 h and progressed to late apoptosis at 24 h post-transduction. In particular, in MDA-MB 468 cells the
percentages of early apoptotic cells (lower right quadrant) shifted from 3.08% in NT cells to 2.77% and
12.38%, at 6 and 24 h post-transduction respectively, while the percentages of late apoptotic cells (upper
right quadrant) increased from 6.49% in NT cells to 8.03% and 17.20% at 6 and 24 h post-transduction,
respectively. Instead, in BT-549 the percentages of early apoptotic cells (lower right quadrant) shifted from
3.39% in NT cells to 6.80% and 4.26%, at 6 and 24 h post-transduction respectively, while the percentages
of late apoptotic cells (upper right quadrant) changed from 10.69% in NT cells to 9.08% and 33.53% at
6 and 24 h post-transduction, respectively. To further confirm the induction of apoptosis in MDA-MB
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468 and BT-549 cells, the DNA breaks occurring during the latest stages of apoptosis were evaluated by
TUNEL assay. As shown in Figure 9C, U94+ cells were TUNEL+ (FITC+), whereas NT cells were found
to be TUNEL− in both MDA-MB 468 and BT-549 cells. Taken together, these data demonstrate that the
expression of U94 triggers apoptosis in different TNBCs.
Figure 9. U94 induces cell cycle arrest, inhibition of DNA repair and apoptosis in MDA-MB 468 and
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BT-549 cell lines. (A) mRNA level of CDKN3, NCAPG2, NUF2 and HMGB1 was determined by
real-time-PCR in MDA-MB 468 cells (upper panel) and BT-549 (lower panel). (B) MDA-MB 468 and
BT-549 cells, 6 and 24 h post-transduction, were stained with Annexin V-FITC and PI. Apoptosis was
assessed by flow cytometry. The four quadrants represent living cells (lower left), early apoptotic (lower
right), late apoptosis (upper right) or necrotic (upper left) stages. Values represent the percentages of
each quadrant. (C) Terminal deoxynucleotidyl transferase-mediated dUTP Nick End Labeling (TUNEL)
staining in MDA-MB 468 and BT-549 cells transduced or not with amplicons for 24 h. DAPI staining
was used to visualize the cell nucleus. The histograms represent the mean ± SD of apoptotic cells from
two independent experiments performed in triplicate. Statistical analysis was performed by unpaired
Student’s t-test, * p < 0.05 and ** p < 0.01. Scale bar: 100 µm.
3. Discussion
Standard chemotherapy for cancer aims to produce replication stress-induced DNA damage
thereby promoting cell death. The ability of cancer cells to recognize this damage and initiate
DNA repair is an important mechanism for drug resistance and poor therapeutic efficacy [55]. As a
consequence, new approaches employing novel compounds and different mechanisms are needed. As
such, the possibility of supporting the current anticancer therapies by making tumors more susceptible
to inhibitors of DNA repair mechanisms may represent an interesting outcome for developing new
anticancer approaches.
Lack of apoptosis is considered as one of the symptoms of tumorigenicity [56], whereas the
induction of apoptosis represents a key target for cancer therapy [57]. Our data highlight the ability
of U94 to exert anticancer activity on TNBC by inhibiting DNA damage repair genes, cell cycle and
eventually leading to intrinsic apoptotic cell death. Indeed, U94 was found to downregulate the
antiapoptotic marker Bcl-2 and upregulate the expression of proapoptotic markers, such as Bax and
Bad, leading to caspase-9 and PARP cleavage. Interestingly, the viral protein was found to operate
synergistically with DNA-damaging drugs but not with microtubule inhibitors. This cooperation
occurs by different mechanisms. DNA-damaging drugs operate by directly targeting to DNA. For
instance, doxorubicin is able to intercalate the DNA via its insertion between the planar DNA base
pairs [58] whereas cisplatin binds to and cross-links DNA which affects DNA strand synthesis and
replication [59]. On the other hand, U94 is able to inhibit the DNA repair mechanisms at gene level by
downmodulating the transcription of genes specifically involved in DNA damage repair. It has been
demonstrated that U94 is a nuclear targeting protein [16], therefore it is more likely to hypothesize that
it exerts its activity in the nucleus. Further studies will be necessary to identify the nuclear targets,
if any, of the viral protein. The relevance of U94 as a therapeutic molecule against TNBC resides in
the evidence of its cancer cell killing effect in the absence of toxicity on normal cells, such as human
primary endothelial cells [16]. In light of our evidence, U94 can be considered a DNA damage response
(DDR) inhibitor. The DNA repair is strictly linked to the DDR, which involves cellular mechanism that
safeguards against DNA damage and that has been recognized as an important innate tumor suppressor
pathway [60,61]. It is worth noting that cancers deficient in DNA mismatch repair display a favorable
prognosis [62]. Tumors carrying a high number of mutations respond well to immunotherapy [63–65]
and the inhibition of DNA repair induces neo-antigens generation and impairs tumor growth [66].
Recent data showed that the permanent block of specific tumor suppressors involved in DNA repair
might be applied for developing new therapeutic approaches [66]. In this context, it is likely that a
continuous activity of U94 in the inhibition of DNA repair processes in immunocompetent individuals
may well trigger a long-lasting immune surveillance leading to a better disease outcome for patients.
Overall, the most interesting aspect of U94 is that its activity is carried out by assaulting tumor cells
from different sides and with different mechanisms of action. Indeed, our previous study demonstrated
that U94 is able to induce a transient blockage of cell cycle and proliferation together with a partial
mesenchymal to epithelial transition (MET) of MDA-MB 231 cells. Interestingly, these effects were
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also evident in vivo [23]. Indeed, U94+ MDA-MB 231 cells generated very small and compact tumor
masses which lack blood vessel infiltration, and have no ability to invade the surrounding adipose
tissue compared to control, U94− cells. Moreover, compared to U94− tumors, the U94+ ones were
characterized by a more differentiated phenotype. This evidence suggests that those MDA-MB 231 cells
which do not respond to the U94-induced DNA damage and apoptosis undergo a MET and regress to
a less aggressive phenotype. However, the possibility that cells with low proliferative capacity and
refractory to U94 effects cannot be ruled out. Altogether, this knowledge led to hypothesize that cells
resistant to the inhibition of DNA repair induced by U94 are likely to acquire proliferative disadvantage
as compared to control cells.
Our microarray data also highlighted the ability of U94 to block the cholesterol biosynthesis
pathway. The impact of cholesterol on oncogenic events, such as tumor development, cell migration
and angiogenesis has been widely recognized [67,68] and, as a consequence, targeting cholesterol
pathways is now considered a potential powerful strategy for cancer therapy [68]. In this context, the
ability of U94 to target the cholesterol synthesis in tumor cells acquires a fundamental role, which
deserves to be deeply investigated. The ability of U94 to interfere with cancer cell proliferation and,
at the same time, to promote apoptosis points to the evidence that the viral protein acts as a cell
killer in two ways on one side, by blocking DNA repair and, on the other side, by inhibiting the
cholesterol synthesis.
U94 is also known to inhibit angiogenesis and lymphangiogenesis by stimulating the release of
a soluble factor(s) [23]. Recently, we demonstrated that U94 induces upmodulation and release of
HLA-G in ECs, and that this remodulation is directly related to the inhibition of angiogenetic properties
observed in ECs upon U94 expression [69].
In conclusion, the ability of U94 to attack tumor cells with different mechanisms attests for the
great potential of this molecule as anticancer agent. U94 showed to be a potential chemotherapy
sensitizer for the selective killing of cancer cells that are deficient in DNA repair. Due to its multi-target
activity, U94 represents a promising therapeutic TNBC treatment as a single agent or in combination.
4. Materials and Methods
4.1. Cell Cultures
Human breast cancer cells (MDA-MB 231, MDA-MB 468 and BT-549) were obtained
from the American Type Culture Collection (ATCC) and grown according to ATCC product
sheet recommendations.
4.2. Cell Transduction
The U94-expressing herpes simplex type-1 (HSV-1) amplicon vectors were constructed, produced
and titrated as previously described [23]. Transduction of tumor cells was performed by incubating
cells for 3 h in serum-free medium containing or not U94 or EGFP-expressing amplicons at multiplicity
of infection (MOI) 1. Cells were then washed and incubated in complete medium. Transduction
efficiency was assessed by flow cytometry.
In specific experiments, such as the Annexin V and the TUNNEL assay, cells were transduced
with an amplicon vector expressing U94 only to avoid fluorescence interferences.
4.3. Reagents
Cisplatin, doxorubicin and taxol were purchased from Accord Healthcare Italia s.r.l. (Milan, Italy).
4.4. Gene Expression Profile and Bioinformatic Analysis
Not treated (NT), EGFP-expressing (EGFP+) and U94-expressing (U94+) cells (four replicates for
each experimental condition) were subjected to microarray analysis to compare their gene expression
profiles. Gene expression profiles were performed by the Integrated Biology Platform of Applied
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Research and Technology Development, Fondazione IRCCS Istituto Nazionale dei Tumori di Milano
(Milan, Italy). Twenty-four h post-transduction, mRNA was isolated using the RNeasy Mini Kit (Qiagen,
Valencia, CA, USA) according to manufacturer’s instructions. After quality check and quantification by
4200TapeStation (Agilent Technologies, Santa Clara, CA, USA) and Qubit Fluorometer (ThermoFisher
Scientific, Waltham, MA, USA), respectively, RNA expression was assessed using the human Affymetrix
Clariom S (Affymetrix ThermoFisher Scientific). Specifically, 100 ng of total RNA was used to generate
the single-stranded cDNA samples for hybridization. Then, cDNA was enzymatically fragmented and
biotinylated using the WT Terminal Labeling kit (ThermoFisher), combined with the hybridization
buffer, and injected into the Human Clariom S arrays (Affymetrix ThermoFisher Scientific) targeting
>20,000 well-annotated genes. Arrays were stained using the Affymetrix®GeneChip®Fluidics
Station 450 and scanned with the 7G Affymetrix®GeneChip®Scanner 3000 (Affymetrix ThermoFisher
Scientific). Raw data were pre-processed using RMA (Irizarry rma) as implemented in the oligo package
of Bioconductor. Normalized data were collapsed from probe- to gene-level using the collapseRows
function [70] of the WGCNA R package, selecting for each gene the probe with highest variation across
samples [71]. The final dataset used in the present study included expression data of 18537 unique
genes. Hierarchical clustering and Principal Component Analysis (PCA) analyses were performed
using Partek software (Partek Inc., St. Louis, MO, USA).
Class comparison between U94+ and EGFP+ transduced cells was performed using log2 normalized
data and limma R package [72]. Genes were considered statistically significant at a false-discovery rate
(FDR) < 0.05. Pathways and networks significantly regulated in gene expression upon U94 expression
were examined using the Core Analysis function included in Ingenuity Pathway Analysis (IPA, Qiagen
Redwood City, CA, USA).
Pre-ranked Gene set enrichment analysis (GSEAPreranked) using javaGSEA Desktop Application
v3.0 (http://www.broadinstitute.org/gsea/index.jsp) [28] was performed for functional analysis of our
dataset. Genes were ranked according to the t test value retrieved from limma analysis. Pathways
with FDR < 0.25 and nominal p value < 0.01 were considered statistically significant.
4.5. Real-Time PCR
The mRNA expression level of CDKN3, NCAPG2, NUF2 and HMGB1 was evaluated by Real-time
PCR on the same stored frozen RNA used for microarray analysis. Total RNA was reverse-transcribed
using the High-Capacity RNA-to-cDNA™Kit (ThermoFisher Scientific). Real-time PCR was performed
using TaqMan®Fast Universal PCR Master Mix (Applied Biosystems-Thermo Fisher Scientific) and
StepOnePlus™ Real-Time PCR System (ThermoFisher Scientific), with the following TaqMan®gene
expression assays (Applied Biosystems-Thermo Fisher Scientific) CDKN3 (Hs00193192_m1), NCAPG2
(Hs00914667_m1), NUF2 (Hs00230097_m1) and HMGB1 (Hs01923466_g1). The expression of each
gene was normalized to β2M gene (Hs99999907_m1). Results are presented as 2−∆Ct, as previously
reported [73].
4.6. Annexin V Assay
Annexin V assay is based on the detection of phosphatidylserine on the outer leaflet of the plasma
membrane of cells, a characteristic of early apoptosis. Annexin assay was conducted using Annexin
V-FITC Apoptosis Detection kit (Calbiochem, San Diego, CA, USA) and performed on cells transducted
or not with different amplicons at different time points according to the manufacturer’s instructions.
Briefly, after transduction cells were harvested and washed twice in cold PBS and resuspended at a
concentration of 106 cells/ml in 1× binding buffer. An aliquot of 500 µL was incubated with 1.25 µL
Annexin V-FITC for 15 min in the dark at room temperature. Then, cells were centrifuged and
resuspended in 500 µL of 1× binding buffer 10 µL of Propidium Iodide were added to each sample,
and the fluorescein-5-isothiocyanate (FITC) and PI fluorescence were measured using flow cytometry
through FL-1 filter (530 nm) and FL-2 filter (585 nm). Viable cells were annexin V negative and
PI negative, early apoptotic cells were annexin V positive and PI negative, and late apoptotic cells
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or necrotic cells were annexin V positive and PI positive. Cells were analyzed by flow cytometry
(FACScan, Becton Dickinson, San Jose, CA, USA) according to the manufacturer instructions.
4.7. Western Blot Analysis
MDA-MB 231cells (2 × 106) were transducted or not with different amplicons and cultured for 6,
12, 24 and 48 h. Then, cells were lysed in 500 µL of 50 mM Tris–HCl, 150 mM NaCl, 1% NP-40, 0.5%
sodium deoxycholate, 2 mM sodium fluoride, 2 mM EDTA, 0.1% SDS, containing a mixture of protease
inhibitors (aprotinin, phenylmethylsulfonyl fluoride, and sodium orthovanadate; Sigma-Aldrich, St.
Louis, MO, USA) for total protein extraction. Equal amounts of proteins were resolved on 8 or 12%
SDS-polyacrylamide gel, transferred to a nitrocellulose membrane and probed with, Poly (ADP-ribose)
polymerase (PARP), Bcl-2, Bax, Bad, pBad, caspase-3, caspase-8 and caspase-9 specific antibodies (Santa
Cruz, Biotechnology, CA, USA). To ensure equal loading and transfer, all membranes were stripped and
incubated with anti-Actin antibody (Santa Cruz Biotechnology). The antigen-antibody complex was
detected by incubation of the membranes with peroxidase-coupled goat anti-mouse or goat anti-rabbit
antibodies and revealed using the ECL System (Amersham Pharmacia, Buckinghamshire, UK).
4.8. Terminal Deoxynucleotidyl Transferase dUTP Nick End Labeling (TUNEL) Assay
Apoptosis was determined by enzymatic labeling of DNA strand breaks using terminal
deoxynucleotidyl transferase-mediated deoxyuridine triphosphate nick end-labeling (TUNEL). TUNEL
labeling was conducted using APO-BrdU™ TUNEL Assay Kit (Promega, Madison, WI, USA) and
performed according to the manufacturer’s instructions. Briefly, cells transduced or not with the
amplicon for 24 and 48 h, were fixed in freshly prepared 4% paraformaldehyde solution in PBS (pH
7.4) for 25 min at 4 ◦C. After fixation, cells were permeabilized in 0.2% Triton®X-100 solution in PBS
for 5 min. After washing twice with washing buffer for 5 min, the cells were covered with 100 µL of
equilibration buffer at room temperature for 5–10 min. The labeling reaction was performed using
terminal deoxynucleotidyl transferase end-labeling TdT and fluorescein-dUTP cocktail for each sample
and incubated for 1 h at 37 ◦C where TdT catalyzes the binding of fluorescein-dUTP to free 3′OH ends
in the nicked DNA. After rinsing, cells were washed with 20× SSC solution buffer and subsequently
incubated with 100 µL of 4′,6-diamidino-2-phenylindole (DAPI; Sigma) to stain nuclei, protected from
light, analyzed and photographed by using a fluorescence microscope (20× objective).
4.9. Chemotherapeutic Drugs Cytotoxic Activity on MDA-MB 231 Cell Line Upon U94 Expression
MDA-MB 231 breast cancer cell line was seeded at a density of 1.75 × 105 cells in a 24-well
plate. Twenty-four hours after seeding, cells were transduced as described above. Cytotoxicity was
assessed by growth inhibition assay after a 24 h exposure to cisplatin (100 µM), doxorubicin (10 µM)
or taxol (50 µM). Each experimental sample was run in quadruplicate. At the end of treatment, each
well was washed with PBS to remove dead cells and debris. The remaining cells were detached
from plate using Trypsin/EDTA (Corning, New York, NY, USA), resuspended in ISOTON®II Diluent
(Beckman Coulter Life Sciences, Indianapolis, Indiana, IN, USA) and counted using Z2™ COULTER
COUNTER®Analyzer (Beckman Coulter Life Sciences).
4.10. Statistical Analysis
Data obtained from multiple independent experiments are expressed as the mean ± standard
deviation (SD) or standard error of the mean (SEM). Principal Component Analysis (PCA) was applied.
Data were analyzed for statistical significance using Fisher’s exact test, One-way ANOVA followed by
Tukey’s post hoc test or Two-way ANOVA followed by Sidak’s multiple comparison test. Differences
were considered significant when p < 0.05. Statistical tests were performed using GraphPad Prism
software (GraphPad Software, La Jolla, CA, USA).
Cancers 2019, 11, 1006 17 of 20
5. Conclusions
The emergence of refractory cancer, in particular of TNBC, against the current anticancer drugs
is worrying. To overcome the resistance and toxicity issues of current anti-cancer therapies, newer
strategies need to be adopted. In this setting, U94 represents a promising therapeutic TNBC treatment
as a single agent or in combination. It is a potential chemotherapy sensitizer for the selective killing of
cancer cells that are deficient in DNA repair.
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